Companies / CMB

CAMBIUM BIO LIMITED

ASX:CMBPharmaceuticals, Biotechnology & Life Sciences
29.4M shares on issueASX (delayed) · as of 28 July 2026$0.43price · delayed$12.7Mmarket cap · indicative
NR
Dilution grade

Not rated — share-count series unreliable

Cash runway2.3 quarters of funding
Share-count growth (24m)no data — share-count series unreliable
Raise cadence (24m)8 cash raises
Options & rights overhang2.1% of shares
In-the-money supply0.0% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

CAMBIUM BIO LIMITED's ordinary share count stands at 29M as of July 2026; the provider notes the share-count series is unreliable. The company raised capital eight times in the 24‑month window for total disclosed proceeds of A$33.0M, most recently a A$1.0M placement in July 2026. Options and rights could convert into 623,629 new shares, equal to 2.1% of the current share count, with 0% in the money at present. At the March 2026 quarter the company reported A$2.1M in cash, equivalent to 2.3 quarters of cover. One proposed securities issue (Appendix 3B) is pending with a nearest proposed date in July 2026.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
2.1%
Max option dilution
0.0%
ITM option dilution
7
Raises · last 12 months
2.3 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 29.4M per ASX (delayed) (28 July 2026).
15.6M20.7M25.8MDec 24Sept 25July 26Cash raise · 22 July 2026Cash raise · 11 Feb 2026Cash raise · 20 Jan 2026Cash raise · 19 Jan 2026Cash raise · 15 Sept 2025Cash raise · 30 July 2025Cash raise · 29 July 2025

Cash runway

2.3 qtrs
Two to four quarters of funding at the recent spend rate.
$2.1M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
23 July 20262A · quoted issueCMB : ORDINARY FULLY PAID29.4MAppendix 2A
16 Mar 20262A · quoted issueCMB : ORDINARY FULLY PAID27.3MAppendix 2A
16 Oct 20252A · quoted issueCMB : ORDINARY FULLY PAID23.0MAppendix 2A
16 Oct 20253G · unquotedCMB : ORDINARY FULLY PAID22.9MAppendix 3G
28 Aug 20252A · quoted issueCMB : ORDINARY FULLY PAID22.9MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

8 cash raises in the last 24 months · 7 in the last 12 months

$1.0M
Placement
22 July 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Join the waitlist

Options & convertible securities

2.1%
Total overhang · of current shares
0.0%
In the money · at current price
624k
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
17 Mar 2026YU-HUNG SEBASTIAN TSENGOther4.4M——3Y notice
16 Oct 2025TERENCE ALLEN WALTSOther55k120k—3Y notice
16 Oct 2025EDMUND KEMP WALLEROther60k120k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026Change in substantial holding - BW
23 July 2026Cleansing Notice
23 July 2026Application for quotation of securities - CMB
21 July 2026Proposed issue of securities - CMB
21 July 2026$PCambium Bio Raises A$1.0 Million via Placement
24 June 2026Becoming a substantial holder
24 June 2026Change in substantial holding - ZYBT
16 June 2026Becoming a substantial holder
27 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
23 Apr 2026$PFDA Confirms Single Pivotal Trial Pathway for Elate Ocular
24 Mar 2026Change of Directors Interest Notice - ST
16 Mar 2026Cleansing Notice
16 Mar 2026Application for quotation of securities - CMB
16 Mar 2026Results of General Meeting
19 Feb 2026$PHalf Year Report and Accounts
10 Feb 2026Proposed issue of securities - CMB
10 Feb 2026Notice of General Meeting/Proxy Form
22 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
19 Jan 2026Proposed issue of securities - CMB
19 Jan 2026$PCambium Bio Secures A$2.4 Million Strategic Investment

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.